This data visualization tool would normally cost $249 for a lifetime license, but now you can get it for only $14.97. Whether you’re creating flowcharts, org charts, floor plans, or network ...

(RTTNews) - 4D Molecular Therapeutics (FDMT) announced positive initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM clinical trial evaluating 4D-150 in a broad ...

4D Molecular (FDMT) Therapeutics announced topline interim data from Part 1 of the SPECTRA clinical trial evaluating 4D-150 in diabetic macular edema and alignment with the U.S. Food and Drug ...

In today's digital age, data is vital. It drives innovation, growth, and decision-making. But data alone is not enough. We need to make sense of it, to find the hidden patterns, trends, and ...

Introduction: Intracranial 4D flow MRI enables quantitative assessment of hemodynamics in patients with intracranial atherosclerotic disease (ICAD). However, quantitative assessments are still ...

The t-SNE ("t-distributed Stochastic Neighbor Embedding") technique is a method for visualizing high-dimensional data. The basic t-SNE technique is very specific: It converts data with three or more ...

Monday, 4D Molecular Therapeutics FDMT released interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (wet AMD) patients.

(Reuters) - Shares of 4D Molecular Therapeutics more than doubled on Monday after the therapy developer reported results from a mid-stage trial of its eye disease therapy. The stock hit an over ...

4D Molecular Therapeutics (NASDAQ:FDMT) shares surged over 60% premarket after the company reported positive interim data for its eye disease drug, 4D-150. Data consists of 24-week results from a ...

He’s the co-founder of Virtualitics, a startup developing software to help companies visualize — and gain insights, with any luck — from their data. “Common dashboard tools fall short of ...

and further safety data updates, are expected to be reported in H1 2024. We expect to have initial discussions with the FDA on Phase 3 pivotal trial design for 4D-150 for patients with wet AMD in Q4 ...